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Magnetic ﬂuid hyperthermia (MFH) with chemically synthesized nanoparticles is currently used in clinical trials as it destroys tumor
cells with an extremely localized deposition of thermal energy. In this paper, we investigated an MFH protocol based on magnetic
nanoparticles naturally produced by magnetotactic bacteria: magnetosomes. (e eﬃcacy of such protocol is tested in a xenograft
model of glioblastoma. Mice receive a single intratumoral injection of magnetosomes, and they are exposed three times in a week to
an alternating magnetic ﬁeld with concurrent temperature measurements. MRI is used to visualize the nanoparticles and to monitor
tumor size before and after the treatment. Statistically signiﬁcant inhibition of the tumor growth is detected in subjects exposed to the
alternating magnetic ﬁeld compared to control groups. Moreover, thanks to magnetosomes high transversal relaxivity, their eﬀective
delivery to the tumor tissue is monitored byMRI. It is apparent that the eﬃcacy of this protocol is limited by inhomogeneous delivery
of magnetosomes to tumor tissue. (ese results suggest that naturally synthesized magnetosomes could be eﬀectively considered as
theranostic agent candidates for hyperthermia based on iron oxide nanoparticles.
1. Introduction
Glioblastoma multiforme is the most frequent and malignant
type of glioma, with a mean survival of fewer than 15 months
despite the advances in diagnoses and treatments now
available [1, 2]. Novel therapeutic agents and approaches to
increase the survival rates, as well as clinical protocols to
eventually cure this type of disease, are thus highly needed.
In oncology, the term hyperthermia refers to the treat-
ment of malignant diseases by administering heat in various
ways.(e process of rising body temperature, either locally or
globally for medical purposes, is usually applied as an adjunct
to an already established treatment modality (radiotherapy
and chemotherapy). Temperatures in the range of 40–46°C are
needed to trigger cancer cell apoptosis by temperature-driven
alterations in molecular pathways. At the same time, local
temperatures should be maintained under 44°C to avoid
damage to tissues surrounding the target, and the whole body
temperature should remain under 42°C, which is the upper
limit compatible with life [3, 4]. Conventional thermotherapy
procedures use diﬀerent energy sources for the generation of
heat within the tissue: radiofrequency waves, ultrasound, and
electric or magnetic ﬁelds [5, 6]. (e cellular eﬀect of thermal
energy deposition is very complicated. Brieﬂy, hyperthermia
may kill or weaken tumor cells and is controlled to limit
eﬀects on healthy cells. Tumor tissues are characterized by
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a disorganized and compact vascular structure which nega-
tively impacts on tissue perfusion, thus reducing their ca-
pabilities to eﬃciently dissipate heat induced by energy
transfer. It is proven that intense heating will cause dena-
turation of proteins and other biochemical consequences
(slowed cell division, altered molecular pathways, and
inhibited synthesis of proteins) that ultimately lead to cell
apoptosis [7]. On the contrary, healthy tissues around the
tumor can more easily maintain the temperature in the
physiological range and compensate for mild heating stress,
minimizing the eﬀects of hyperthermia [3].
Within this frame, magnetic ﬂuid hyperthermia (MFH)
represents a further development in the area [8] and is
currently under testing in some preclinical studies [9] and
clinical trials [10]. (is method delivers thermal energy to
the target region by superparamagnetic iron oxide nano-
particles exposed to an alternating magnetic ﬁeld (AMF):
when magnetic nanoparticles (MNPs) are injected in the
tumor and an AMF is applied, the tumor temperature rises
and results in extremely selective thermal ablation of tumor
cells [11].
MNPs such as magnetite, hematite, and maghemite,
which aremainly obtained by chemical synthesis, are themost
frequently investigated nanoparticles for biomedical appli-
cations because of their biocompatibility [12]. Recently, re-
searchers have devoted their attention to a class of iron oxide
MNPs naturally produced by magnetotactic bacteria, named
magnetosomes (MNs) [13–15]. Magnetosomes are widely
described in the literature and well characterized in terms of
magnetic properties, interactions with living tissues, and
thermal eﬃciency [16–18]. MNs are characterized by a very
high speciﬁc absorption rate (SAR), a measurement of their
eﬃciency in transforming the energy of the applied magnetic
ﬁeld into heat, and high T2 relaxivity, relevant for their vi-
sualization in MRI [17]. Alphandery et al. [16] have applied
chains of magnetosomes extracted from Magnetospirillum
magneticum to treat experimental models of breast cancer.
Previous work from our group [19] suggested a possible
application ofMFH protocols that make use ofMNs extracted
from Magnetospirillum gryphiswaldense. Magnetosomes
extracted from Magnetospirillum gryphiswaldense have been
characterized as potential contrast agents for MRI [17] by
measuring their longitudinal and transversal relaxivity: they
have been recognized as eﬀective contrast agents for MRI
since they are characterized by r2≈ 200mM−1·s−1 at 4.7 T [18].
In this paper, we report the application of chains of mag-
netosomes extracted from Magnetospirillum gryphiswaldense
in an experimental model of glioma with speciﬁc attention to
their theranostic properties, that is, the capability to act as
contrast agents in MRI and as agents for magnetic ﬂuid
hyperthermia. (is work aims at further investigating the
biocompatibility of MNs on cancer cell cultures and quan-
titatively evaluating the outcome of intratumoral heating
therapy in a xenograft murine model of glioblastoma. (e
MFH protocol presented here was designed paying serious
attention towards the translational value of the method,
putting adequate resting periods in between exposures and
adopting levels of thermal energy deposition constrained by
biosafety limits for human trials.
2. Materials and Methods
2.1. Production and Extraction of MNs. Magnetosomes were
extracted from Magnetospirillum gryphiswaldense MSR-1
culture and puriﬁed according to the protocol proposed by
Gru¨nberg et al. [19] and detailed in Mannucci et al. [17] After
puriﬁcation, MNs were dried for 5 h using a lyophilizer, ir-
radiated with c rays (56Gy for 84min) and ﬁnally stored at−20°C. For their use in in vitro/in vivo experiments, MNs
were dispersed in PBS and sonicated until the suspensions
appeared homogeneous and transparent at visual inspection.
2.2. In Vitro Experiments and Cell Cultures. Human
glioblastoma-astrocytoma, epithelial-like cells (U87MG,
purchased by ATCC Manassas, VA), were cultured as de-
tailed in Supplementary Information S1.
(e internalization of MNs into U87MG cells was assessed
by optical microscopy. After incubation with MNs (experi-
mental details reported in Supplementary Information S2),
cells were double stained with Prussian blue, to visualize iron,
and Nuclear Fast Red (Bioptica, Italy), to visualize cell nuclei.
U87MG cells were observed at 10x, 20x, and 40xmagniﬁcation
using an optical Olympus microscope (BX-URA2, Olympus
optical, GMBH, Hamburg, Germany) equipped with Image
ProPlus software (Media Cybernetics, Rockville, USA). For
transmission electronmicroscopy (TEM), U87MG cancer cells
were plated on a 2.4 cm culture glass, stained with lead citrate,
and observed using Philips Morgagni TEM and equipped with
a Megaview II camera for digital image acquisition as de-
scribed in Supplementary Information S3.
Cell viability (CV) was evaluated by the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
test. Cells were plated at a density of 5000 cells per well in 96-
well plates and incubated at 37°C in a mixture of air and 5%
CO2. After 24 h, the medium was replaced with fresh medium
containing 1, 0.5, and 0.2mg/ml of sterilized MNs, re-
spectively. After 6, 12, and 24 h of incubation, 100 µl of MTT
(at 5mg/ml concentration, purchased from Sigma, Italy) was
added to each well and incubated for additional 4 h (37°C, 5%
CO2). Afterward, plates were removed from the incubator,
and formazan crystals, which originate from plasma mem-
brane electron transport in viable cells, were dissolved in
100 µl of DMSO (Sigma, Italy). (e multiwell was placed into
a monochromator (ChroMate Awareness Technology) for the
measurement of absorbance at 570 and 630 nm. Four mea-
surements of optical density (OD) were recorded for each
sample, and cell viability (%) was calculated with the following
equation: CV%� (ODsample/ODcontrol)× 100.
2.3. In Vivo Experiments: Experimental Design and 5er-
motherapyProtocol. (irty-two nude homozygote male mice
(Harlan Laboratories, Udine, Italy) were maintained under
standard environmental conditions (temperature, humidity,
and 12 h/12 h light/dark cycle, with water and food ad libi-
tum) under veterinarian control in the animal facility of the
University of Verona. (e experimental plan received au-
thorization from the Italian Ministry of Health (approval
numbers 27/2012-B) and was approved by the Animal Care
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and Use Committee of the University of Verona. Animal
work was conducted following Italian law (D.L. 4 March 2014
no. 26) and the European Union normative (2010/63/EU).
Major eﬀorts were performed to minimize the number of
animals and to avoid their suﬀering. A graphical illustration of
the experimental protocol timeline is reported in Figure 1.
One million U87MG cells resuspended in 200 µl of sterile PBS
were subcutaneously injected in the right ﬂank of anesthetized
mice. (e size of the tumor mass was measured every other
day with a hand-held caliper, and the gross volume was
calculated as (D∗ d2)/2, [20] where D�maximum diameter
and d�minimum diameter of the mass.When tumor volume
reached 100 µl (30± 5 days after cells injection), magnetic
resonance imaging (MRI) was performed to check their ef-
fective volume. At this point, mice were randomly divided in
three groups: (i) n � 10, animals received intratumorally
100 µl of saline (Group S); (ii) n � 10, animals received 1.5mg
of MNs diluted in 100 µl of PBS using an intradermal needle
(27G) (Group M); (iii) n � 12, animals received 1.5mg of
MNs diluted in 100 µl of PBS (Group HT) and were exposed
to AMF every other day for one week after injection of MNs.
(e AMF apparatus (Magnetherm, nano(erics UK) yields
a magnetic ﬁeld intensity of 23 kA/m (≈29mT) and frequency
of 110 kHz.(ese values are very close to those used in human
application of hyperthermia [8]. Mice were placed on a cus-
tom animal holder under isoﬂuorane anesthesia 1.5% (For-
ane, Abbott) and exposed to AMF for 20min. A digital IR
camera (Flir I7, Flir Systems, Italy) was used to take snapshots
of heating distribution in the tumor and surrounding tissues.
In addition to the thermal camera, a multichannel ther-
mometer equipped with optical ﬁber probes (FOTEMP4,
Optocon AG, Germany) was used to assess temperature
variation within the tumor and the body. Under anesthesia,
probes were placed by a nonmetallic catheter inside the tumor
mass and under the skin of the contralateral ﬂank of the
mouse; temperature was continuously recorded during AMF
exposures. All mice were monitored by MRI before, 24 h, one
week and two weeks after the intratumor injection ofMNs (or
saline).(e ﬁrst time point was acquired tomeasure the initial
tumor volume; the second time point was chosen to evaluate
the intratumor distribution of MNs, and the last time points
served to monitor the eﬃcacy of MFH in reducing tumor
mass. Following the last MRI scan, mice were sacriﬁced by
isoﬂuorane overdose and by neck dislocation; the tumors
were then excised for histological analysis. Animals were
placed prone in a heated MRI animal holder, and a 3.5 cm i.d.
transmitter/receiver birdcage coil was used. T2- and
T∗2 -weighted images were acquired to detect the tumor and
the presence of MNs, respectively. MR imaging details are
reported in Supplementary Information S4.
To measure the volume of tumors, MR images were
processed with custom software coded in MATLAB
(MathWorks, Natick, MA). (e tumor area was manually
selected slice by slice by entering a series of points and
extracting the polygon represented by this set of points. (e
polygon area was then segmented into three parts: the total
tumor surface, the region occupied by magnetosomes, and
their diﬀerence, which corresponds to the area of the tumor
that is free of magnetosomes.(e portion of the polygon that
contains MNs was then extracted via Otsu’s thresholding.
(e percentual increase in tumor volume was calculated at
each time point as 100∗ (V(t)/V(0)), where V(t) is the total
tumor volume at time t and V(0) is the initial volume.
2.4. Histology. After the last MRI acquisition, animals were
sacriﬁced. Tumors were excised, washed, and embedded in
paraﬃn, and details on the procedure are available in
Supplementary Information S5. Sections were ultimately
stained with Prussian blue and Nuclear Fast Red (Bioptica,
Italy) to visualize iron nanoparticles and nuclei,
respectively.
MNs Extr. MRI Pre MRI Post temp. meas. MRI 1 w MRI 2 w
Cells U87MG inj. MNs inj. 3X AMF exp.
Figure 1: Experimental protocol timeline. Magnetosomes were extracted and injected in tumors under MRI monitoring; same scans were
used to measure the pretreatment size of the tumor. (ermal maps and local temperature variations were measured during hyperthermic
treatment. Upon completion of thermotherapy, immediately prior to histology, a new MRI session was conducted to measure the ﬁnal
volume of tumors.
Contrast Media & Molecular Imaging 3
3. Results
3.1. In Vitro Experiments. TEM images of magnetotactic
bacteria observed by a backscattered electron detector clearly
show the organization of MNs in chains along the longi-
tudinal axis of bacteria (Figure 2(a)) and the cuboctahedral
structure of single nanoparticles (Figure 2(b)), as reported by
Mannucci et al. [17]. (e MNs preparations used in the
present work were previously characterized for chemical and
physical properties [18]. Brieﬂy, the nanocrystal size is 42±
9 nm, and MNs show a superparamagnetic behaviour and
are characterized by transversal relaxivity comparable to that
of commercial superparamagnetic contrast agents. Impor-
tantly, the presence of a phospholipid membrane provides
a good protection against oxidation so that the MNs oxi-
dation state is stable over months. (e speciﬁc absorption
rate (SAR) was also measured by applying an alternate
magnetic ﬁeld of 17 kA/m and 183 kHz and resulted in
482.7± 50.8W/g per mass of iron, a value that is among the
highest reported in the literature.
(e uptake of MNs by U87MG cancer cells was in-
vestigated by TEM and Prussian blue staining of U87MG
cells after incubation with MNs; the eﬀect of varying MNs
concentration in the culture medium and incubation time
was investigated. Qualitative analysis of Prussian blue
stained samples showed that the best condition for in-
ternalization was 0.2mg/ml of puriﬁed and sterilized MNs
for an incubation time of 24 h. TEM was used to investigate
in deep the cellular sites of MNs uptake. As a general ﬁnding,
TEM images revealed that MNs are distributed on the
cellular membrane, within the cytoplasm and near the
nucleus (Figures 2(c) and 2(d)). MTT assay revealed neg-
ligible cellular toxicity of sterilized MNs. Results of toxicity
tests are reported in Figure 2(g): diﬀerent MNs amounts
(1mg/ml, 0.5mg/ml, and 0.2mg/ml) incubated for diﬀerent
time periods (6, 12, and 24 h) showed no statistically sig-
niﬁcant eﬀect on cells viability. It could be surprising that an
increase in optical absorbance was detected after 24 h of
incubation with MNs that could be interpreted as an in-
crease in cell viability or proliferation induced by MNs.
However, such an increase was not statistically signiﬁcant.
3.2. In Vivo Experiments. Temperature variations in animals
treated with AMF were measured during the exposure both
with thermal IR camera and optical ﬁber thermometer.
Figures 3(a) and 3(b) report representative thermal maps
acquired during (a) or immediately after (b) application of
AMF in one mouse belonging to the HT group; the higher
temperature of the tumor compared to the body is visible on
the right ﬂank as indicated by the arrow (Figure 3(b)). We
should mention that it was not possible to record thermal
maps for all subjects: some major issues such as anatomical
localization of the tumor and subsequent positioning of the
Control 0.2 mg/ml 0.5 mg/ml 1 mg/ml
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Figure 2: In vitro characterization of MNs. (a) TEM of whole-mount of bacteria (scale bar, 500 nm). (b) MNs after isolation of
M. gryphiswaldense (scale bar, 100 nm). (c, d) TEM of the internalization of MNs with U87MG cells: MNs are visible in cytoplasm vacuoles
(scale bar, (c) 2000 nm and (d) 1000 nm). (e, f) Cellular uptake: representative histological images of MNs-treated cells after 24 h of
incubation with 0.2 and 0.5mg/ml of MNs (Prussian blue staining; scale bar, 50 µm). (g) MTTassay on U87MG cells after incubation with
MNs: MTT assay shows a negligible cytotoxic eﬀect of MNs, percent viability of cells incubated with MNs is expressed relative to control
cells. Error bars refer to SEM.
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animal inside the coil did prevent the tumor mass to be
visible through the viewﬁnder of the camera. Optical ﬁber
probes were used instead of the sample body and tumor
temperature in each subject every 10 s for the whole ex-
posure time and recorded for later processing. Figure 3(c)
shows the diﬀerence of temperature ΔT (mean± SEM)
between the tumor and body. Heating of the tumormass was
recorded, and the diﬀerence with the measured body tem-
perature became statistically signiﬁcant after about 8min of
exposure, as reported in Figure 3(c).
Volumetric T2w MR images were obtained for each
subject both for experimental and control groups. A ﬁrst set
of images was necessary to assess the initial volume of the
tumor; these were lately used as reference to calculate the
percentage increase in tumor volume. Immediately after
the administration of MNs, but prior to hyperthermia treat-
ment, a second set of images was acquired to localize MNs
within the tumor masses. An additional set of images was
acquired immediately after the treatment (1w) and one week
later (2 w) to evaluate eﬃcacy of the therapy and to estimate
the ﬁnal volume of tumors. For each experimental group,
representative MR images of the development of U87MG
tumors are reported in Figure 4. Figures 4(a)–4(d) report the
growth of tumors for Group S, administered with saline
only. At 2w time point, the MR signal of the mass is in-
homogeneous, with signs of tissue degeneration marked by
areas of moderate hyperintensity. Figures 4(e)–4(h) show
the progression of the tumor in Group M. (ese mice did
not receive any MFH treatment. MNs inside the tumor mass
are clearly detectable as dark areas. Figures 4(i)–4(l) show
the tumor evolution in one animal treated with MFH. One
week after injection, the almost complete remission of the
tumor after MFH treatment, with only a thin layer of
neoplastic tissue, was visible. (e eﬀect was also evident in
the picture of this subject at this time point (Figures 4(n) and
4(o)), where necrotic tissue is well visible at the tumor site.
(is eﬀect was detected for two subjects in Group HT, while
the remaining showed only minor signs of tissue damage at
the macroscopic level. From Figure 4(j), it is clearly evident
that, 24 h after administration, there is a fraction of the
tumor volume completely free from nanoparticles since it
appears hyperintense in T2w images with signal intensity
similar to the preinjection value (Figure 4(i)). In the sub-
sequent images (Figures 4(j) and 4(k)), the fraction of the
(a) (b)
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Figure 3: Analysis of temperature within tumormass. (a)(ermal map acquired with the animal placed inside the coil. (b) Two ROIs placed
on the thermal maps of the body and tumor immediately after the treatment. (c) Diﬀerence between the tumor and body temperature
measured by optical ﬁber probes as a function of exposure time; data are reported as average± SEM. Diﬀerence between the body and tumor
become statistically signiﬁcant after about 8min of exposure.
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Figure 4: MR images of representative animals. (a–d) Animal treated with saline injection; images acquired before saline injection (a), 24 h
(b), one week (c), and two weeks (d) after saline injection. (e–h) Animal treated with MNs injection; images acquired before MNs injection
(e), 24 h (f ), one week (g), and two weeks (h) afterMNs injection. (i–l) Animal treated withMNs injection with AMF; images acquired before
MNs injection (i), 24 h (j), one week (k), and two weeks (l) after MNs injection. (m) shows the relative tumor size for the three experimental
groups as a function of time (∗p< 0.05). (n) and (o) show two pictures of a representative animal treated with AMF and MNs in which we
obtained good response to thermotherapy.
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tumor volume that was initially free from magnetosomes
keeps growing while MFH eﬃcacy is limited to the central
region of the tumor where magnetosomes were eﬃciently
delivered. In order to better show how intratumoral in-
jection produces inhomogeneous distribution of MNs
within tumor tissue, in Figure 5 we have reported with high
magniﬁcation representative MR images of tumors acquired
prior to and 24 h after administration of MNs in four
representative mice. By comparing pre- and post-treatment
images, it can be clearly seen that within the tumor region,
there are areas almost completely free of MNs (showing
hyperintense signal equal to pretreatment) and regions with
high MNs content (showing hypointense signal at the level
of background noise). (ese ﬁndings indicate that eﬃcient
and homogeneous intratumoral delivery of magnetosomes is
crucial and that their diagnostic property, namely, the ca-
pability to substantially aﬀect MRI signal intensity, is of
paramount importance in future clinical applications. Rel-
ative tumor size for each experimental group, as a function
of time, is reported in Figure 4(m). Values are expressed as
percentage of the initial size, measured before administra-
tion of MNs or saline, for each subject. Data were reported as
mean± SEM. At the ﬁrst time point, upon completion of
MFH therapy, the size of Group HT is reduced when
compared to control groups (relative tumor size: 161± 23%,
314± 33%, and 300± 36% for Groups HT, M, and S, resp.).
One week later, at time point 2 w, the relative tumor size in
the HTgroup remains smaller than in the remaining groups
(371± 58% (HT), 602± 106% (M), and 626± 124% (S)).
Statistical signiﬁcance was tested among the three groups by
one way ANOVA: relative tumor size for Group HT is
signiﬁcantly lower than tumor size for both Groups M and S
at 1 w (p< 0.01), while the diﬀerence was not statistically
signiﬁcant between the two controls.
3.3. Histology. Tumors treated with sterile saline solution
(Group S, Figures 6(a) and 6(b)) exhibit little to no
modiﬁcations in the parenchyma with a good preservation
of cellular morphology. Spontaneous necrosis occurred in
the deeper portion of the mass due to a reduction of
capillary density in those areas. Histological slices of tu-
mors belonging to Groups HT and M showed the presence
of MNs, clearly identiﬁed by blue staining. In particular,
slices of tumors treated with MNs but not exposed to AMF
(Group M, Figures 6(c) and 6(d)) showed no evident signs
of cytotoxic eﬀects in regions were large amounts of Fe
were detected by Prussian blue staining. Moreover, the
nanoparticles were clustered closer to the injection’s sites
and were detectable also in tumor parenchyma, even if in
lower concentrations. In tumors treated with MNs and
exposed to AMF (Figures 6(e) and 6(f )), large necrotic
areas characterized by a paucity of cells and the presence of
thin collagen ﬁbers that substitute dead tissue were visible
in diﬀerent portions of tumor slices. Moreover, the pres-
ence of clustered MNs within the edges of necrotic lesions
could be an evidence of the eﬀectiveness of hyperthermic
treatment associated with the administration of MNs.
Figures 6(e) and 6(f ) also show that necrotic areas have
reduced blue staining probably due to lymphatic drainage
of MNs.
4. Discussion
Iron oxide magnetic nanoparticles are known to generate
heat because of molecular vibration in the presence of AMF
[9]. MFH is a fairly new concept that ﬁnds its applications in
the treatment of diﬀerent types of cancers previously loaded
with MNPs and exposed to an AMF. (e key mechanism of
this treatment is based on the intracellular heat stress
resulting in activation of several cellular degradation pro-
cesses (protein denaturation, reduced perfusion, and
changes in pH, among others), which ultimately lead to
apoptosis [21, 22]. Magnetosomes are proven to be equally
eﬀective both for therapy, as heating mediators, and for MR
imaging, as contrast agents [23]: these properties can qualify
this class of naturally synthesized nanoparticles as thera-
nostic agents. In previous work, we tested the theranostic
properties of MNs on a xenograft colon cancer model [17];
here, we have further developed our protocol for MFH and
demonstrated in vivo the substantial inhibition of the tumor
growth in a murine model of glioblastoma multiforme. (e
proposed method is minimally invasive, and a standard MRI
session can provide evidence on the eﬃcacy of the treatment,
progression of the disease, and tracking of the antitumoral
magnetic agents at the same time: a convenient feature
towards future clinical applications.
Our MRI images, acquired at diﬀerent time points
during cancer progression, have demonstrated that, after
intratumoral injection, MNs remained within the tumor for
the whole period of observation with no evidence of mi-
gration to other organs or tissues, as also conﬁrmed by other
groups [16, 24]. (is feature allows for repeated and highly
speciﬁc AMF treatments after a single administration of the
magnetic material, minimizing unwanted side eﬀects
(e.g., heating of body regions not aﬀected by the disease and
thus not involved in the treatment plan). (e distribution of
MNs strongly depends on the route of administration.
Today, one of the most critical challenges in hyperthermia is
the accumulation of magnetic agents in the tumor after
systemic administration [25, 26]. (eir removal from the
blood stream, the development of methods to increase
speciﬁc tissue uptake, and consequently avoiding unwanted
accumulation in healthy tissues are currently among the
major unresolved issues in the ﬁeld. Until these challenges
are resolved, intratumoral injection remains the most ef-
fective technique to load a suﬃcient amount of the magnetic
material within a neoplastic mass for therapeutic purposes
[26, 27]. (anks to high transversal relaxivity, eﬀective and
homogeneous delivery of MNs to tumor tissue by intra-
tumoral injection can be monitored by MRI and possibly
improved before MFH treatment. (ermal maps of our
animals exposed to AMF and treated with MNs show a well-
deﬁned area of increased temperature corresponding to the
whole volume of the tumor. At the same time, the body
temperature sampled from the contralateral ﬂank of the
subject remains constant for the entire duration of the
AMF application. (e homogeneous and selective heating,
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measured on the surface of the implanted glioblastoma and
conﬁrmed by optical temperature probes, can be explained
by the presence of well-localized clusters of MNs, a hy-
pothesis conﬁrmed by MRI and histology. (ese heating
spots can generate intratumoral temperature gradients that
might lead to cancer cell death within a certain distance from
the MNs [24], an eﬀect that could partially compensate the
uneven distribution of nanoparticles in the tumor.
(e temperature increase produced by MNs in the tu-
mors of our experiments was lower than values commonly
reported for MFH [28, 29]. However, it has been recently
reported that local heating decays exponentially with
(a) (b)
(c) (d)
(e) (f )
(g) (h)
Figure 5: Intratumor injection produces highly inhomogeneous distribution of MNs within tumor tissue. Representative images of tumors
acquired before (a, c, e, g) and 24 h after (b, d, f, h) injection of MNs.Within the tumor region, there are areas almost completely free of MNs
(asterisks) and regions with high MNs content (arrows).
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increasing distance from the nanoparticle surface over a few
nanometers [30] so a moderate increase in the temperature,
as measured by optical ﬁber probes, may indeed correspond
to substantially higher increases at the nanoparticle surface.
Concerning approaches for tumor regression, similar
ﬁndings were described by other groups, and some evidence
is supporting the hypothesis that less aggressive therapies
could produce results comparable to more radical treat-
ments [24, 31]. (e moderate—yet highly eﬀective—heating
we achieved during AMF exposure could be explained by the
interaction of MNs with the surrounding environment.
Despite the elevate SAR value measured for lyophilized
samples of MNs [18], their heating eﬃciency could be re-
duced when they are included in a living tissue [32, 33].
Biological structures as cellular membranes and vesicles
could lead to immobilization of the nanoparticles and
minimization of Brownian motion with subsequent partial
restriction of heating mechanisms [34]. Being aware of these
potential limitations, we found that heating power emanated
by MNs induced a marked alteration in tumors that received
MFH treatment; such eﬀect ultimately resulted in a signiﬁ-
cant reduction of tumor size after the therapy. On the
contrary, in the absence of AMF, MNs are inert: their sole
presence inside the neoplastic mass did not aﬀect tumor
growth.
We have also recorded the almost complete remission of
the tumor in two mice immediately after the treatment, with
mild signs of burn on the skin and more severe eﬀects in the
100 µm
(a)
50 µm
(b)
100 µm
MNs
(c)
50 µm
MNs
(d)
100 µm
MNs
NECR.
(e)
50 µm
MNs
NECR.
(f )
Figure 6: Histological analysis of tumors. (a, b) Histological sections of tumors treated with saline. Morphology of cancer cells is preserved
with negligible signs of tissue modiﬁcations. (c, d) In tumors treated only with MNs, nanoparticles are clearly marked by Prussian blue
staining. No evident signs of cytotoxic eﬀects were detectable. (e, f ) Tumors injected withMNs and exposed to AMF showed clusters of MNs
surrounded by large areas of tissue necrosis induced by hyperthermic treatment (scale bar, 100 µm and 50 µm for the left and right column,
resp.).
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core portion of the tumor as a consequence of thermal
energy release.Minor signs of tissue damage were visible also
at the rim of the xenograft implant, while similar eﬀects in
the surrounding healthy tissues were completely absent. In
a previous work [16], important results were reported in
experimental breast tumors treated with MNs extracted
from M. magneticum AMB-1 and exposed, three times in
a week on alternate days, to an AMF of 183 kHz and 40mT
(∼32 kA/m) strength. Another group [24] described valuable
outcomes with chemically synthesized magnetic nano-
particles on a xenograft breast cancer model, although using
a diﬀerent protocol for AMF: animals were exposed for
60min at days 0 and 7, at 435 kHz and 15.4 kA/m strength.
Magnetosomes extracted from M. gryphiswaldense MSR-1
are proven to induce mild tissue damage at a frequency of
187 kHz and magnetic ﬁeld strength of 23 kA/m
(H0ν� 4.3∗109 Am−1·s−1) [17]. Here, we have improved
the MFH protocol and measured a global reduction of
tumor growth, convincing antitumoral activity with set-
tings (frequency � 110 kHz, AMF strength � 23 kA/m, and
H0ν� 2.5∗109Am−1·s−1) that aremuch closer to those employed
in human studies [9].Moreover, these settings deliver a product
H0ν which is below the estimated tolerance threshold limit for
tissue safety, as reported by Hergt et al. [35], for small exposed
volumes: H0ν < 5 ∗109 Am−1·s−1. Nevertheless, it is worth to
mention that the value H0ν� 2.5∗109 reported by Herg et al.
is not a well-established maximum value but rather an arbi-
trarily chosen reference value.
(ere are some key aspects that, despite a certain degree
of similarity, mark essential diﬀerences between these
studies: the tumor model, the nanoparticles used for therapy,
and the application of AMF, hence the comparison is ob-
viously not straightforward. Regarding thermal eﬃciency, all
the magnetic materials perform very well: SAR values lean
towards synthetic nanoparticles, but both types of natural
MNs exhibit excellent physical and thermal properties.
Remarkable results regarding thermoablation of the tumor
(thanks to elevated hyperthermic temperatures) and sig-
niﬁcant shrinking of tumors with a much moderate, thus
highly eﬀective, temperature increase were reported.
However, AMF settings proposed in these studies could
generate nonspeciﬁc tissue heating caused by induced eddy
currents [35]. Here, we obtained a substantial, although not
complete, thermoablation of tumors and statistically rele-
vant slowdown of their growth while retaining biosafety-
compliant AMF settings, a less radical approach that
maintains its therapeutic eﬀectiveness under clinical con-
straints for patient’s safety.
It is interesting to note that, despite the good results
attained immediately after the treatment, one week later we
observed recovery in the growth rate: an additional ﬁnding
in agreement with the abovementioned studies. It can be
hypothesized that active cancer cells survived on the outer
regions of the lesion, as conﬁrmed by morphological MR
imaging. T2w images of animals that better responded to
therapy with the almost complete remission of the tumor
showed indeed the presence of some residual malignant
tissue. (is progressive and unwanted proliferation of the
tumor mass might be explained by the route of
administration: although carefully fractionated, intra-
tumoral injections could not ensure a uniform distribution
of nanoparticles within the mass. Elevated interstitial
pressure, combined with irregularities in the circulating
blood ﬂow, is among the main issues that prevent the re-
distribution of MNs and their subsequent uptake by cancer
cells [36]. To obtain a homogeneous distribution of MNs
within the tumor tissue, an MRI-guided intratumoral ad-
ministration of MNs is advisable. For the whole duration of
the experiment, we did not record any evidence of de-
generation or alterations in the distribution of nanoparticles:
the substantial parenchymal stability, which was non-
invasively observed by longitudinal MR imaging and veriﬁed
at a later stage ex vivo by histology, suggests that repeated
hyperthermia treatments after single administration of
magnetic material are feasible with evident beneﬁcial eﬀects
for tumor regression. (is paper has some limitations re-
garding the translational validity of the experimental model
of glioblastoma used. First, a recent investigation of the
origin of the used cell line, U87MG commercially available,
performed by advanced techniques of genetic proﬁling and
transcriptome analysis [37] showed that the DNA proﬁle of
commercial U87MG cells is diﬀerent from that of the
original cell line. Second, the growth pattern and micro-
environment of subcutaneous tumors are very diﬀerent from
those of intracranial tumors potentially limiting the trans-
lational validity of the obtained results. However, the
abovementioned investigation [37] concluded that the
commercially available U87MG cell line is of “CNS origin
and is likely to be a bona ﬁde human glioblastoma cell line,”
and moreover, subcutaneous models of brain tumors are
widely applied in pharmaceutical research. Although the
abovementioned issues must be taken into account, the present
study has translational validity. However, in future in-
vestigations, we plan to apply the developed technique to the
orthotopic model of brain tumors obtained from other well-
characterized publicly available cell lines.
5. Conclusions
Synthetic magnetic nanoparticles have been widely con-
sidered for a long time as diagnostic and therapeutic agents
in preclinical and clinical studies [38–41]. In this work, we
have explored the theranostic potential of chains of mag-
netosomes, magnetic nanoparticles naturally produced by
magnetotactic bacteria. We have shown that MFH based on
magnetosomes lead to a clear slowdown of tumor growth
with signiﬁcant therapeutic eﬀects. (ese results were
achieved with a measured temperature increase much lower
than values commonly reported in the literature, and the
temperature increase strongly depends on the simultaneous
application of both MNs and AMF. (e sole presence of
MNs inside the tumor mass does not elicit any cytotoxic
response nor signiﬁcant eﬀects on tumor volumes. Im-
provement to the proposed protocol could include opti-
mization of AMF parameters and exposure times to better
exploit the heating power of magnetosomes. Moreover, we
have applied MRI to monitor the distribution of MNs within
the tumor tissue along the therapeutic treatment, and we
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have demonstrated that inhomogeneous distribution of
MNs inside tumor tissue may strongly limit their therapeutic
eﬃcacy. (e functionalization of MNs to target U87MG
cancer cells would also be desirable: a highly tissue-speciﬁc
delivery would improve the uptake of magnetic material and
thus the clinical outcome of therapies.
Data Availability
Electronic supplementary information with detailed ex-
perimental methods is available online or from the authors.
Disclosure
(e funders had no role in the study design, data collection,
and analysis. (e abstract of this paper was presented at the
29th Annual Meeting of the European Society for Hyper-
thermic Oncology in Torino (IT), as a traditional poster
presentation with interim ﬁndings. Moreover, a part of this
work was presented as an oral communication at the 103rd
National Meeting of the Italian Physical Society (Trento,
Italy, September 2017). (e actual paper, however, has never
been published elsewhere in any printed or electronic form.
(e present address of Stefano Tambalo is Center for Neu-
roscience and Cognitive Systems @UniTn, Istituto Italiano di
Tecnologia, Corso Bettini 31, 38068 Rovereto, Italy.
Conflicts of Interest
(e authors declare that there are no conﬂicts of interest.
Authors’ Contributions
Silvia Mannucci and Stefano Tambalo contributed equally to
the paper.
Acknowledgments
(e authors acknowledge Associazione Italiana per la Ricerca
sul Cancro for the ﬁnancial support (Project no. 11993, area:
targeted therapy, and type of grant: IG). (e ﬁnancial support
of Italian Ministry of Education, University and Research
(MIUR) through the project FIRB Riname RBAP114AMK is
also acknowledged.
Supplementary Materials
(e supplementary material ﬁle reports details on the ex-
perimental procedures followed in the paper. Speciﬁcally, it
reports experimental details on cancer cell culture (In-
formation S1), investigation of MNs uptake in cancer cells
(Information S2), transmission electron microscopy (TEM)
of cells incubated with MNs (Information S3), magnetic
resonance imaging (Information S4), and histology (In-
formation S5). (Supplementary Materials)
References
[1] A. A. Brandes, A. Tosoni, E. Franceschi, M. Reni, G. Gatta, and
C. Vecht, “Glioblastoma in adults,” Critical Reviews in On-
cology/Hematology, vol. 67, no. 2, pp. 139–152, 2008.
[2] P. Y. Wen and S. Kesari, “Malignant gliomas in adults,” New
England Journal of Medicine, vol. 359, no. 5, pp. 492–507,
2008.
[3] G. Hegyi, G. P. Szigeti, and A. Szasz, “Hyperthermia versus
oncothermia: cellular eﬀects in complementary cancer ther-
apy,” Evidence-Based Complementary and Alternative Medi-
cine, vol. 2013, Article ID 672873, 12 pages, 2013.
[4] R. Cavaliere, E. C. Ciocatto, B. C. Giovanella et al., “Selective
heat sensitivity of cancer cells. Biochemical and clinical
studies,” Cancer, vol. 20, no. 9, pp. 1351–1381, 1967.
[5] P. Wust, B. Hildebrandt, G. Sreenivasa et al., “Hyperthermia
in combined treatment of cancer,”5e Lancet Oncology, vol. 3,
no. 8, pp. 487–497, 2002.
[6] A. Jordan, R. Scholz, K. Maier-Hauﬀ et al., “(e eﬀect of
thermotherapy usingmagnetic nanoparticles on rat malignant
glioma,” Journal of Neuro-Oncology, vol. 78, no. 1, pp. 7–14,
2006.
[7] B. Hildebrandt, P. Wust, O. Ahlers et al., “(e cellular and
molecular basis of hyperthermia,” Critical Reviews in On-
cology/Hematology, vol. 43, no. 1, pp. 33–56, 2002.
[8] B. Kozissnik, A. C. Bohorquez, J. Dobson, and C. Rinaldi,
“Magnetic ﬂuid hyperthermia: advances, challenges, and
opportunity,” International Journal of Hyperthermia, vol. 29,
no. 8, pp. 706–714, 2013.
[9] K. A. Court, H. Hatakeyama, S. Y. Wu et al., “HSP70 in-
hibition synergistically enhances the eﬀects of magnetic ﬂuid
hyperthermia in ovarian cancer,” Molecular Cancer 5era-
peutics, vol. 16, no. 5, pp. 966–976, 2017.
[10] M. Johannsen, B. (iesen, P. Wust, and A. Jordan, “Magnetic
nanoparticle hyperthermia for prostate cancer,” International
Journal of Hyperthermia, vol. 26, no. 8, pp. 790–795, 2010.
[11] A. Ito, M. Shinkai, H. Honda, and T. Kobayashi, “Medical
application of functionalized magnetic nanoparticles,” Jour-
nal of Bioscience and Bioengineering, vol. 100, no. 1, pp. 1–11,
2005.
[12] J. Mosayebi, M. Kiyasatfar, and S. Laurent, “Synthesis,
functionalization, and design of magnetic nanoparticles for
theranostic applications,” Advanced Healthcare Materials,
vol. 6, no. 23, article 1700306, 2017.
[13] S. Bellini, Su di un Particolare Comportamento di Batteri
d’acqua Dolce (On a Unique Behavior of Freshwater Bacteria),
Institute of Microbiology, University of Pavia, Pavia, Italy,
1963a.
[14] S. Bellini, Ulteriori studi sui “Batteri magnetosensibili” (Fur-
ther Studies on Magnetosensitive Bacteria), Institute of Mi-
crobiology, University of Pavia, Pavia, Italy, 1963b.
[15] R. Blakmore, “Magnetotactic bacteria,” Science, vol. 190,
no. 4212, pp. 377–379, 1975.
[16] E. Alphande´ry, S. Faure, O. Seksek, F. Guyot, and I. Chebbi,
“Chains of MN extracted from AMB-1 magnetotactic bacteria
for application in alternative magnetic ﬁeld cancer therapy,”
ACS Nano, vol. 5, no. 8, pp. 6279–6296, 2011.
[17] S. Mannucci, L. Ghin, G. Conti et al., “Magnetic nanoparticles
from Magnetospirillum gryphiswaldense increase the eﬃcacy
of thermotherapy in a model of colon carcinoma,” PLoS One,
vol. 9, no. 10, Article ID e108959, 2014.
[18] T. Orlando, S. Mannucci, E. Fantechi et al., “Characterization
of magnetic nanoparticles from Magnetospirillum gry-
phiswaldense as potential theranostics tools,” Contrast Media
& Molecular Imaging, vol. 11, no. 2, pp. 139–145, 2016.
[19] K. Gru¨nberg, E. C. Mu¨ller, A. Otto et al., “Biochemical and
proteomic analysis of the MNmembrane inMagnetospirillum
gryphiswaldense,” Applied and Environmental Microbiology,
vol. 70, no. 2, pp. 1040–1050, 2004.
Contrast Media & Molecular Imaging 11
[20] P. Marzola, S. Ramponi, E. Nicolato et al., “Eﬀect of tamoxifen
in an experimental model of breast tumor studied by dynamic
contrast-enhanced magnetic resonance imaging and diﬀerent
contrast agents,” Investigative Radiology, vol. 40, no. 7,
pp. 421–429, 2005.
[21] A. Laszlo, “(e eﬀects of hyperthermia on mammalian cell
structure and function,” Cell Proliferation, vol. 25, no. 2,
pp. 59–87, 1992.
[22] K. C. Kregel, “Heat shock proteins: modifying factors in
physiological stress responses and acquired thermotolerance,”
Journal of Applied Physiology, vol. 92, no. 5, pp. 2177–2186,
2002.
[23] M. R. Benoit, D. Mayer, Y. Barak et al., “Visualizing implanted
tumors in mice with magnetic resonance imaging using
magnetotactic bacteria,” Clinical Cancer Research, vol. 15,
no. 16, pp. 5170–5177, 2009.
[24] S. Kossatz, R. Ludwig, H. Da¨hring et al., “High therapeutic
eﬃciency of magnetic hyperthermia in xenograft models
achieved with moderate temperature dosages in the tumor
area,” Pharmaceutical Research, vol. 31, no. 12, pp. 3274–3288,
2014.
[25] A. Cervadoro, C. Giverso, R. Pande et al., “Design maps for
the hyperthermic treatment of tumors with super-
paramagnetic nanoparticles,” PLoS One, vol. 8, no. 2, Article
ID e57332, 2013.
[26] T. R. Pearce, K. Shroﬀ, and E. Kokkoli, “Peptide targeted lipid
nanoparticles for anticancer drug delivery,” Advanced Ma-
terials, vol. 24, no. 28, pp. 3803–3822, 2012.
[27] I. Hilger and W. A. Kaiser, “Iron oxide-based nanostructures
for MRI and magnetic hyperthermia,” Nanomedicine, vol. 7,
no. 9, pp. 1443–1459, 2012.
[28] A. Jordan, R. Scholz, P. Wust et al., “Eﬀects of magnetic ﬂuid
hyperthermia (MFH) on C3H mammary carcinoma in vivo,”
International Journal of Hyperthermia, vol. 13, no. 6,
pp. 587–605, 1997.
[29] M. Johannsen, B. (iesen, A. Jordan et al., “Magnetic ﬂuid
hyperthermia (MFH) reduces prostate cancer growth in the
orthotopic Dunning R3327 rat model,” 5e Prostate, vol. 64,
no. 3, pp. 283–292, 2005.
[30] A. Riedinger, P. Guardia, A. Curcio et al., “Subnanometer
local temperature probing and remotely controlled drug re-
lease based on azo-functionalized iron oxide nanoparticles,”
Nano Letters, vol. 13, no. 6, pp. 2399–2406, 2013.
[31] R. K. Jain, “Normalization of tumor vasculature: an emerging
concept in antiangiogenic therapy,” Science, vol. 307, no. 5706,
pp. 58–62, 2005.
[32] S. Dutz, M. Kettering, I. Hilger, R. Mu¨ller, and M. Zeisberger,
“Magnetic multicore nanoparticles for hyperthermia-
inﬂuence of particle immobilization in tumour tissue on
magnetic properties,” Nanotechnology, vol. 22, no. 26, article
265102, 2011.
[33] H. Richter, M. Kettering, F. Wiekhorst, U. Steinhoﬀ, I. Hilger,
and L. Trahms, “Magnetorelaxometry for localization and
quantiﬁcation of magnetic nanoparticles for thermal ablation
studies,” Physics in Medicine and Biology, vol. 55, no. 3,
pp. 623–633, 2010.
[34] M. Kallumadil, M. Tada, T. Nakagawa, M. Abe, P. Southern,
and Q. A. Pankhurst, “Suitability of commercial colloids for
magnetic hyperthermia,” Journal of Magnetism and Magnetic
Materials, vol. 321, no. 21, pp. 3650-3651, 2009.
[35] R. Hergt, S. Dutz, and M. Ro¨der, “Eﬀects of size distribution
on hysteresis losses of magnetic nanoparticles for hyper-
thermia,” Journal of Physics: CondensedMatter, vol. 20, no. 38,
article 385214, 2008.
[36] J. W. Nichols and Y. H. Bae, “Odyssey of a cancer nano-
particle: from injection site to site of action,” Nano Today,
vol. 7, no. 6, pp. 606–618, 2012.
[37] M. Allen, M. Bjerke, H. Edlund, S. Nelander, and
B. Westermark, “Origin of the U87MG glioma cell line: good
news and bad news,” Science Translational Medicine, vol. 8,
no. 354, p. 354re3, 2016.
[38] P. Marzola, B. Longoni, E. Szilagyi et al., “In vivo visualization
of transplanted pancreatic islets by MRI: comparison between
in vivo, histological and electron microscopy ﬁndings,”
Contrast Media & Molecular Imaging, vol. 4, no. 3, pp. 135–
142, 2009.
[39] S. Tambalo, L. Peruzzotti-Jametti, R. Rigolio et al., “Magnetic
resonance imaging of rats with experimental autoimmune
encephalomyelitis reveals brain cortex remodeling,” Journal of
Neuroscience, vol. 35, no. 27, pp. 10088–10100, 2015.
[40] Y. X. Wa´ng and J. M. Ide´e, “A comprehensive literatures
update of clinical researches of superparamagnetic resonance
iron oxide nanoparticles for magnetic resonance imaging,”
Quantitative Imaging in Medicine and Surgery, vol. 7, no. 1,
pp. 88–122, 2017.
[41] L. Zhu, Z. Zhou, H. Mao, and L. Yang, “Magnetic nano-
particles for precision oncology: theranostic magnetic iron
oxide nanoparticles for image-guided and targeted cancer
therapy,” Nanomedicine, vol. 12, no. 1, pp. 73–87, 2017.
12 Contrast Media & Molecular Imaging
